.jpg?format=webp&quality=80&width=3840)
In this study, researchers enhanced the efficacy of a hepatocellular carcinoma (HCC) targeting system using a conditionally replicative adenovirus (CRAd) delivered by human umbilical cord-derived mesenchymal stem cells (HUMSCs). They addressed the limitations caused by the alpha-fetoprotein (AFP) heterogeneity of HCC by incorporating a bispecific T cell engager (BiTE) targeting programmed death ligand 1 controlled by the human telomerase reverse transcriptase promoter. The new system demonstrated improved anti-tumor effects with reduced damage to extrahepatic organs and less liver injury. It also enhanced T cell infiltration and activation in tumor tissues. Moreover, the new system efficiently eliminated AFP-negative cells in AFP heterogeneous tumor models. Overall, the new system presented a more effective and safer strategy against HCC than the old one.
Like
Save
Share